Medical School · Year 2 · Gastrointestinal · includes a quiz and discussion video

Lecture 13: Pancreatic Disorders

Unit 2.2: Gastrointestinal System

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the etiology and pathophysiology of acute pancreatitis
2. Explain the clinical presentation, diagnosis, and management of acute pancreatitis
3. Describe chronic pancreatitis and its complications
4. Explain pancreatic cystic lesions and their management
5. Describe pancreatic cancer risk factors, diagnosis, and treatment
6. Explain pancreatic neuroendocrine tumors

Pancreatic Anatomy and Function

The pancreas occupies a retroperitoneal position, extending transversely across the upper abdomen. The head lies nestled within the C-loop of the duodenum, with the uncinate process projecting posteriorly and medially behind the superior mesenteric vessels. The neck overlies the confluence of the portal and superior mesenteric veins. The body constitutes the main portion, and the tail extends leftward toward the splenic hilum, in close relation to the spleen.

The ductal system drains pancreatic secretions into the duodenum. The main pancreatic duct of Wirsung runs the length of the gland, joining the common bile duct at the ampulla of Vater to enter the duodenum through the major papilla. The accessory duct of Santorini, when present, drains through the minor papilla. Pancreas divisum, occurring in approximately ten percent of the population, represents the most common congenital variant and results from failure of fusion between the dorsal and ventral pancreatic primordia during embryonic development. In this condition, the majority of pancreatic drainage occurs through the smaller minor papilla, which may predispose to recurrent pancreatitis in some individuals.

The exocrine pancreas produces digestive enzymes and bicarbonate. Amylase initiates starch digestion. Lipase, working with colipase, digests dietary triglycerides. Proteolytic enzymes including trypsin, chymotrypsin, and elastase are secreted as inactive zymogens to prevent autodigestion, becoming activated only in the duodenal lumen. Bicarbonate-rich fluid neutralizes gastric acid entering the duodenum, creating the alkaline environment necessary for optimal enzyme function.

The endocrine pancreas, organized into the islets of Langerhans scattered throughout the parenchyma, produces hormones regulating glucose metabolism. Beta cells, comprising about seventy percent of islet cells, secrete insulin in response to elevated glucose. Alpha cells produce glucagon, which raises blood glucose by promoting hepatic glycogenolysis and gluconeogenesis. Delta cells secrete somatostatin, which inhibits both insulin and glucagon release. PP cells produce pancreatic polypeptide, which regulates pancreatic secretion.

<image>Panel A: Pancreatic anatomical position showing head in duodenal C-loop, uncinate process behind superior mesenteric vessels, neck overlying portal/SMV confluence, body, and tail extending to splenic hilum with key vascular relationships. Panel B: Ductal system with main duct of Wirsung joining the common bile duct at the ampulla, accessory duct of Santorini at the minor papilla, and inset of pancreas divisum anatomy. Panel C: Exocrine function diagram showing acinar cells secreting zymogens and ductal cells secreting bicarbonate with activation cascade in the duodenal lumen. Panel D: Endocrine islet illustration with beta cells (insulin, 70%), alpha cells (glucagon, 20%), delta cells (somatostatin, 5%), and PP cells with hormone targets.</image>

Acute Pancreatitis: Etiology

Acute pancreatitis represents inflammation of the pancreas that develops rapidly and may range from mild, self-limited disease to severe, life-threatening illness. Understanding the diverse etiologies enables targeted prevention and management.

Gallstones account for approximately forty percent of acute pancreatitis cases, making cholelithiasis the most common cause overall. The mechanism involves stone passage through the ampulla of Vater, causing transient obstruction of pancreatic drainage. Small stones and biliary microlithiasis (sludge) pose particular risk because they can pass into the common bile duct and impact at the ampulla. Cholecystectomy during the index hospitalization prevents recurrence.

Alcohol causes approximately thirty percent of cases and represents the second most common etiology. Alcoholic pancreatitis typically develops after years of heavy drinking, distinguishing it from the acute effects of alcohol-induced fatty liver. The mechanism involves direct toxicity to acinar cells and premature activation of digestive enzymes. Recurrence is common if alcohol consumption continues.

The mnemonic "I GET SMASHED" captures the major causes: Idiopathic (ten to twenty percent, remaining unexplained after evaluation), Gallstones, Ethanol, Trauma (including post-ERCP pancreatitis occurring in three to five percent of procedures), Steroids (rare), Mumps and other infections, Autoimmune pancreatitis, Scorpion stings (geographic), Hypertriglyceridemia and Hypercalcemia, ERCP, and Drugs.

Hypertriglyceridemia causes approximately five percent of cases when triglyceride levels exceed 1000 mg/dL. The mechanism involves liberation of free fatty acids that exert direct toxic effects on acinar cells. Treatment requires emergent triglyceride lowering through insulin infusion (which activates lipoprotein lipase) or plasmapheresis.

Drug-induced pancreatitis accounts for approximately five percent of cases, with numerous medications implicated. Definite associations include azathioprine, 6-mercaptopurine, valproic acid, and didanosine. Probable associations include ACE inhibitors, statins, and fibrates. The mechanism varies by agent and may involve direct toxicity, hypersensitivity reactions, or metabolic effects.

<image>Panel A: Pie chart of acute pancreatitis causes with gallstones (40%), alcohol (30%), idiopathic (10-20%), hypertriglyceridemia (5%), drugs (5%), post-ERCP (3-5%), and other causes. Panel B: I GET SMASHED mnemonic displayed vertically with each letter expanded and mechanism briefly explained for each etiology. Panel C: Gallstone pancreatitis mechanism showing stone passage from gallbladder through cystic duct into common bile duct, impacting at ampulla, causing transient pancreatic duct obstruction. Panel D: Drug-induced pancreatitis table with definite associations (azathioprine, valproic acid, didanosine), probable associations (ACE inhibitors, statins, fibrates), and timing of onset.</image>

Acute Pancreatitis: Pathophysiology and Classification

The pathophysiology of acute pancreatitis begins with premature activation of trypsinogen to trypsin within the pancreatic parenchyma. Normally, trypsinogen remains inactive until reaching the duodenum, where enterokinase cleaves it to active trypsin. Various insults disrupt this protective mechanism, allowing intracellular or intraparenchymal trypsin activation. Active trypsin then activates other zymogens in a cascade, initiating pancreatic autodigestion. The resulting cellular injury triggers an intense inflammatory response, with release of cytokines, activation of complement, and recruitment of inflammatory cells. This inflammatory cascade can produce systemic inflammatory response syndrome (SIRS), potentially leading to distant organ dysfunction.

The Revised Atlanta Classification distinguishes two morphologic types of acute pancreatitis. Interstitial edematous pancreatitis comprises eighty to ninety percent of cases and involves diffuse inflammation of the pancreatic parenchyma without necrosis. This type usually follows a mild course with resolution within the first week. Necrotizing pancreatitis accounts for ten to twenty percent of cases and involves necrosis of pancreatic parenchyma, peripancreatic tissue, or both. Necrosis typically becomes evident on imaging after 72 to 96 hours and carries significantly higher morbidity and mortality.

Severity classification prognosticates outcomes and guides management intensity. Mild acute pancreatitis involves no organ failure and no local or systemic complications. Moderate acute pancreatitis involves transient organ failure (resolving within 48 hours) or local complications without persistent organ failure. Severe acute pancreatitis involves persistent organ failure lasting more than 48 hours and carries mortality rates of thirty to fifty percent.

Organ failure is assessed using the Modified Marshall scoring system. Respiratory failure is defined as PaO2/FiO2 ratio below 300. Cardiovascular failure is defined as systolic blood pressure below 90 mmHg despite fluid resuscitation, or requirement for vasoactive agents. Renal failure is defined as serum creatinine at or above 1.9 mg/dL. The presence of any organ failure at 48 hours that persists defines severe disease.

<image>Panel A: Cellular mechanism cascade from normal acinar cell through premature trypsinogen-to-trypsin conversion, zymogen activation, autodigestion, cytokine release, and systemic inflammatory response. Panel B: Revised Atlanta Classification comparing interstitial edematous pancreatitis (80-90%, diffuse CT enhancement, usually mild) versus necrotizing pancreatitis (10-20%, non-enhancing areas, higher mortality). Panel C: Severity classification pyramid with mild (no organ failure), moderate (transient organ failure under 48 hours), and severe (persistent organ failure over 48 hours) categories. Panel D: Modified Marshall scoring criteria for respiratory (PaO2/FiO2 less than 300), cardiovascular (SBP less than 90 despite fluids), and renal (creatinine 1.9 or above) organ failure.</image>

Acute Pancreatitis: Clinical Features and Diagnosis

The clinical presentation of acute pancreatitis follows a characteristic pattern. Pain typically localizes to the epigastrium, often radiating through to the back, described as constant and boring rather than colicky. Patients frequently report that leaning forward reduces pain intensity by decreasing stretch on the retroperitoneal pancreas. Nausea and vomiting are nearly universal. Ileus with abdominal distension is common due to inflammation affecting adjacent bowel. Fever may develop, particularly when necrosis or infection supervenes.

Physical examination findings reflect disease severity. In mild cases, the abdomen shows epigastric tenderness without peritonitis. In severe disease, signs of third-spacing and hypovolemia may predominate. Two rare but prognostically ominous signs indicate retroperitoneal hemorrhage: Cullen's sign describes periumbilical ecchymosis from blood tracking along the falciform ligament, while Grey-Turner's sign describes flank ecchymosis from blood dissecting into the retroperitoneal tissue planes.

Laboratory evaluation demonstrates pancreatic enzyme elevation. Serum lipase rises within hours of symptom onset and remains elevated for one to two weeks, making it the preferred diagnostic marker due to greater specificity and longer elevation compared to amylase. Serum amylase also rises early but normalizes within three to five days. Importantly, the degree of enzyme elevation does not correlate with disease severity. Elevated liver function tests, particularly ALT, suggest gallstone etiology. Rising blood urea nitrogen indicates hemoconcentration and predicts worse outcomes. Elevated hematocrit similarly reflects third-spacing and serves as a marker of severity.

Diagnosis requires two of three criteria: characteristic abdominal pain, serum lipase (or amylase) greater than three times the upper limit of normal, and characteristic imaging findings. Most patients meet the first two criteria, making imaging unnecessary for diagnosis in straightforward presentations.

Imaging serves specific purposes beyond diagnosis. Transabdominal ultrasound should be performed in all patients to evaluate for gallstones as the underlying etiology. CT with intravenous contrast is not needed for diagnosis if clinical and laboratory criteria are met but becomes essential for evaluating complications. When obtained to assess for necrosis, CT should be delayed until 72 to 96 hours after symptom onset, as necrosis may not be apparent earlier. MRI with MRCP provides superior evaluation of the biliary tree when choledocholithiasis is suspected.

<image>Panel A: Clinical presentation with epigastric pain radiating to back, forward-leaning posture for relief, and associated symptoms (nausea, vomiting, ileus, fever). Panel B: Physical signs including Cullen's sign (periumbilical ecchymosis) and Grey-Turner's sign (flank ecchymosis) indicating retroperitoneal hemorrhage. Panel C: Laboratory findings comparing lipase versus amylase (sensitivity, specificity, timing, duration) with additional severity markers (BUN, hematocrit) and note that enzyme magnitude does not correlate with severity. Panel D: Diagnostic algorithm showing characteristic pain plus lipase greater than 3 times normal confirming diagnosis, ultrasound for gallstone evaluation, CT at 72-96 hours for complications, and MRCP for suspected choledocholithiasis.</image>

Acute Pancreatitis: Management

Initial management of acute pancreatitis focuses on aggressive supportive care. Intravenous fluid resuscitation addresses the substantial third-space losses that occur with pancreatic inflammation. Lactated Ringer's solution is preferred over normal saline based on evidence of reduced systemic inflammation. Initial infusion rates of 250 to 500 mL per hour are appropriate, with goal-directed adjustment based on urine output (targeting 0.5 to 1 mL/kg/hour), heart rate, and hematocrit trends. Hemodynamically unstable patients require intensive care unit admission.

Pain control should be provided generously, as pancreatic pain is severe. Opioids remain the analgesics of choice. Historical concerns about morphine causing sphincter of Oddi spasm have not been supported by clinical evidence, and there is no reason to avoid morphine specifically.

Nutritional support has undergone paradigm shifts. Traditional practice mandated prolonged NPO status to "rest the pancreas," but evidence now supports early enteral nutrition. In mild pancreatitis, oral feeding should commence once pain is improving and patients are hungry, starting with a low-fat diet. In moderate and severe pancreatitis, enteral nutrition through nasogastric or nasojejunal tubes should be initiated within 24 to 72 hours. Enteral nutrition maintains gut barrier integrity, reduces bacterial translocation, and improves outcomes compared to total parenteral nutrition, which should be reserved for patients who cannot tolerate any enteral intake.

Antibiotics are not indicated for sterile necrosis. Prophylactic antibiotics do not prevent infection of necrotic tissue and may select for resistant organisms. Antibiotics should be initiated only when infected necrosis is documented or strongly suspected, with carbapenems or fluoroquinolone plus metronidazole providing appropriate coverage.

ERCP plays a specific role in biliary pancreatitis. Urgent ERCP within 24 hours is indicated when concurrent cholangitis is present. Persistent biliary obstruction without cholangitis warrants early ERCP. However, gallstone pancreatitis without cholangitis or persistent obstruction does not benefit from urgent ERCP; cholecystectomy should be performed during the same admission to prevent recurrence.

Prognostic scoring systems help identify patients at risk for severe disease. The BISAP score (BUN greater than 25 mg/dL, Impaired mental status, SIRS criteria present, Age greater than 60 years, Pleural effusion) provides bedside assessment at admission. Ranson's criteria include both admission parameters and changes at 48 hours. The APACHE II score offers general ICU severity assessment.

<image>Panel A: Initial resuscitation with IV access, lactated Ringer's fluid resuscitation (250-500 mL/hr), opioid pain control, and goal-directed monitoring of urine output, heart rate, and hematocrit. Panel B: Nutrition algorithm showing oral feeding when pain improves for mild disease, enteral nutrition within 24-72 hours for moderate/severe disease, and TPN only if enteral nutrition is not tolerated. Panel C: Antibiotics and ERCP guidance showing no prophylactic antibiotics for sterile necrosis, antibiotics for infected necrosis, urgent ERCP for cholangitis, and no urgent ERCP for uncomplicated gallstone pancreatitis. Panel D: BISAP scoring system with five components (BUN, impaired mental status, SIRS, age, pleural effusion) and mortality risk stratification.</image>

Acute Pancreatitis: Complications

Local complications of acute pancreatitis evolve over time and are classified by the Revised Atlanta terminology based on timing and contents. Acute peripancreatic fluid collections develop within the first four weeks, lack a defined wall, and usually resolve spontaneously without intervention. Acute necrotic collections also develop within four weeks but contain necrotic material in addition to fluid.

After four weeks, these collections mature and develop encapsulating walls. A pseudocyst is a walled-off collection containing fluid only, without solid necrotic debris. The wall consists of inflammatory fibrous tissue rather than true epithelium, distinguishing pseudocysts from true cysts. Management is conservative if asymptomatic. Symptomatic pseudocysts (causing pain, obstruction, or infection) or those enlarging require drainage, preferably by endoscopic transmural approach (cystogastrostomy or cystoduodenostomy), with percutaneous or surgical drainage as alternatives.

Walled-off necrosis describes encapsulated collections containing both fluid and necrotic debris, maturing after four weeks. This distinction from pseudocysts is critical because walled-off necrosis often requires more aggressive intervention than simple drainage.

Infected necrosis represents the most feared local complication, typically developing two to four weeks after disease onset. Clinical indicators include persistent fever, rising white blood cell count, and failure to improve clinically. CT findings of gas within necrotic collections provide definitive evidence of infection, though absence of gas does not exclude infection. CT-guided fine needle aspiration can obtain culture material when diagnosis is uncertain.

Management of infected necrosis follows the "step-up" approach. Initial treatment with broad-spectrum antibiotics may suffice for mild infections. If clinical improvement does not occur, percutaneous catheter drainage is added. If infection persists despite drainage, minimally invasive or open surgical necrosectomy becomes necessary. This graduated approach has proven superior to early surgical intervention.

Vascular complications require vigilance. Splenic vein thrombosis results from adjacent inflammation and causes left-sided portal hypertension with gastric varices while the main portal vein remains patent. Pseudoaneurysm formation, typically involving the splenic artery or gastroduodenal artery, poses risk of life-threatening hemorrhage. Pancreatic duct disruption can cause pancreatic ascites (high-amylase ascitic fluid) or, if the upstream gland loses continuity with the main duct, a disconnected pancreatic duct syndrome.

<image>Panel A: Timeline diagram of collection evolution showing acute peripancreatic fluid collections and acute necrotic collections (under 4 weeks) maturing to pseudocysts (fluid only) and walled-off necrosis (containing debris) after 4 weeks. Panel B: Pseudocyst management algorithm from observation for asymptomatic cases to endoscopic, percutaneous, or surgical drainage for symptomatic or enlarging collections. Panel C: Infected necrosis panel showing timing (2-4 weeks), clinical signs, CT gas finding, and step-up approach (antibiotics, percutaneous drainage, minimally invasive necrosectomy, open surgery). Panel D: Vascular complications including splenic vein thrombosis with gastric varices, pseudoaneurysm formation, pancreatic ascites, and disconnected pancreatic duct syndrome.</image>

Chronic Pancreatitis

Chronic pancreatitis represents progressive inflammatory disease causing irreversible structural damage to the pancreas, eventually resulting in both exocrine and endocrine insufficiency. Unlike acute pancreatitis, which may recover completely, chronic pancreatitis produces permanent parenchymal destruction with fibrosis and calcification.

The TIGAR-O classification system organizes etiologies. Toxic-metabolic causes predominate, with alcohol accounting for approximately seventy percent of cases in Western countries. Smoking independently contributes to risk and accelerates progression. Hyperlipidemia rarely causes chronic changes. Idiopathic chronic pancreatitis, without identifiable cause, occurs in both early-onset (presenting in adolescence or young adulthood) and late-onset forms. Genetic mutations predispose to pancreatitis through various mechanisms: PRSS1 mutations cause hereditary pancreatitis with autosomal dominant inheritance, SPINK1 mutations reduce trypsin inhibition, and CFTR mutations (including carriers of cystic fibrosis alleles) impair bicarbonate secretion. Autoimmune pancreatitis represents a distinct inflammatory condition responding to immunosuppression. Recurrent acute pancreatitis, regardless of etiology, can progress to chronic disease. Obstructive causes include strictures and pancreas divisum.

Clinical features reflect progressive gland destruction. Pain is the predominant symptom, typically epigastric with radiation to the back, often triggered by eating and leading to food avoidance. Steatorrhea develops when more than ninety percent of exocrine function is lost, producing fatty, foul-smelling, difficult-to-flush stools. Weight loss results from both malabsorption and pain-induced reduction in oral intake. Diabetes mellitus develops as the endocrine pancreas fails, often requiring insulin and being particularly difficult to control due to concurrent glucagon deficiency causing brittle glycemic patterns. Fat-soluble vitamin deficiencies (vitamins A, D, E, and K) result from fat malabsorption.

Diagnosis employs imaging and functional testing. CT demonstrates calcifications (highly specific), dilated pancreatic duct, and glandular atrophy. MRCP reveals ductal abnormalities including the "chain of lakes" appearance of alternating strictures and dilations. Endoscopic ultrasound provides the highest sensitivity for early parenchymal and ductal changes. Fecal elastase below 200 micrograms per gram indicates exocrine insufficiency. Direct secretin stimulation testing, measuring pancreatic bicarbonate response, provides the most sensitive functional assessment but is primarily a research tool.

Management addresses symptoms and complications. Absolute abstinence from alcohol and smoking cessation are essential to slow progression. Pain management should employ a stepwise approach, recognizing that opioid dependence represents a significant risk. Pancreatic enzyme replacement therapy (PERT) treats exocrine insufficiency, providing supplemental lipase, protease, and amylase with meals. A low-fat diet reduces steatorrhea symptoms, and fat-soluble vitamin supplementation prevents deficiency. Diabetes management typically requires insulin. Endoscopic therapy (dilation of dominant strictures, stone removal, stenting) or surgical intervention (lateral pancreaticojejunostomy or Puestow procedure for dilated duct disease; resection for focal disease) addresses ductal obstruction and pseudocysts.

<image>Panel A: TIGAR-O classification showing toxic-metabolic (alcohol 70%, smoking), idiopathic, genetic (PRSS1, SPINK1, CFTR), autoimmune, recurrent acute, and obstructive etiologies. Panel B: Clinical features including epigastric pain radiating to back, steatorrhea (when greater than 90% function lost), weight loss, brittle diabetes from glucagon loss, and fat-soluble vitamin deficiencies. Panel C: Imaging findings with CT calcifications and duct dilation, MRCP chain of lakes appearance, and EUS parenchymal changes. Panel D: Management algorithm from abstinence and pain control through PERT, nutrition with vitamin supplementation, diabetes management, and endoscopic or surgical therapy (Puestow procedure).</image>

Autoimmune Pancreatitis

Autoimmune pancreatitis represents an increasingly recognized inflammatory condition with distinct characteristics that set it apart from other forms of pancreatitis. Recognition is critical because it responds dramatically to corticosteroid therapy and can mimic pancreatic malignancy, potentially leading to unnecessary surgery.

Type 1 autoimmune pancreatitis is part of the IgG4-related disease spectrum, a systemic condition affecting multiple organs through a shared pathophysiology of lymphoplasmacytic infiltration rich in IgG4-positive plasma cells. Type 1 typically affects older men. Serum IgG4 levels are elevated in approximately seventy percent of cases, though this finding lacks specificity. Imaging demonstrates diffuse pancreatic enlargement with loss of normal lobular contour, producing the characteristic "sausage pancreas" appearance. Histologically, the infiltrate demonstrates storiform (whorled) fibrosis and obliterative phlebitis. Extrapancreatic involvement is common and includes sclerosing cholangitis (which can mimic primary sclerosing cholangitis or cholangiocarcinoma), retroperitoneal fibrosis, autoimmune sialadenitis, and interstitial nephritis.

Type 2 autoimmune pancreatitis is pancreas-specific and unrelated to IgG4 disease. It typically affects younger patients and shows no sex predominance. Serum IgG4 levels are normal. The histologic hallmark is granulocytic epithelial lesions within pancreatic ducts. An important association exists with inflammatory bowel disease, present in approximately thirty percent of Type 2 patients.

The HISORt criteria guide diagnosis. Histology shows characteristic features (lymphoplasmacytic infiltrate, storiform fibrosis). Imaging demonstrates diffuse enlargement or a focal mass. Serology reveals elevated IgG4. Other organ involvement consistent with IgG4-related disease supports the diagnosis. Response to steroids provides confirmatory evidence and may itself establish diagnosis in appropriate clinical context.

Treatment centers on corticosteroids. Prednisone at 40 mg daily for four weeks followed by gradual taper produces dramatic clinical and imaging improvement in most patients. Maintenance therapy with low-dose steroids or immunomodulators (azathioprine) may be necessary because relapse occurs in thirty to fifty percent of patients, particularly those with Type 1 disease and extrapancreatic involvement. Re-treatment with steroids is effective for relapse. The excellent response to immunosuppression and potential for serious complications from unnecessary surgery underscore the importance of considering this diagnosis before proceeding to pancreatic resection for presumed malignancy.

<image>Panel A: Type 1 versus Type 2 autoimmune pancreatitis comparison showing IgG4-related disease in older males versus pancreas-specific disease in younger patients with IBD association. Panel B: Type 1 characteristics including sausage pancreas CT appearance, storiform fibrosis histology, and extrapancreatic manifestations (sclerosing cholangitis, retroperitoneal fibrosis, sialadenitis, nephritis). Panel C: HISORt diagnostic criteria covering histology, imaging, serology (elevated IgG4), other organ involvement, and response to steroids. Panel D: Treatment algorithm with prednisone 40 mg for 4 weeks, taper, relapse management with azathioprine maintenance, and emphasis on avoiding unnecessary surgery.</image>

Pancreatic Cystic Lesions

Pancreatic cystic lesions are increasingly detected due to widespread abdominal imaging. Distinguishing benign from premalignant or malignant lesions guides appropriate management, which ranges from observation to surgical resection.

Pseudocysts, discussed previously in the context of pancreatitis complications, are the most common pancreatic cysts and follow pancreatitis or pancreatic trauma. They contain fluid without neoplastic epithelium, representing walled-off inflammatory collections rather than true cysts.

Serous cystadenomas are benign neoplasms with virtually no malignant potential. They typically affect older women and demonstrate characteristic microcystic architecture with numerous small cysts arranged in a honeycomb pattern, often with a central stellate scar. Surgical resection is indicated only for symptomatic lesions.

Mucinous cystic neoplasms occur almost exclusively in women, typically in the body or tail of the pancreas, and do not communicate with the pancreatic duct. They contain mucin-producing epithelium with distinctive ovarian-type stroma. Malignant potential is significant, and all MCNs should be resected in surgical candidates given that invasive carcinoma may be present within the cyst.

Intraductal papillary mucinous neoplasms arise from the ductal epithelium and communicate with the pancreatic duct system. They are classified by their relationship to the main pancreatic duct. Main duct IPMNs involve dilation of the main pancreatic duct to greater than 5 mm and carry high malignancy risk of forty to seventy percent. Branch duct IPMNs involve side branch cysts communicating with an otherwise normal main duct and carry lower malignancy risk of fifteen to twenty-five percent. Mixed IPMNs demonstrate features of both and share the high-risk profile of main duct disease.

Management of branch duct IPMNs follows stratification by worrisome features. High-risk stigmata mandating surgical resection include obstructive jaundice, solid enhancing component within the cyst, and main pancreatic duct dilation exceeding 10 mm. Worrisome features prompting further evaluation with endoscopic ultrasound include cyst size greater than 3 cm, enhancing mural nodule, thickened cyst wall, main duct diameter 5 to 9 mm, abrupt caliber change in the pancreatic duct, and lymphadenopathy.

Cyst fluid analysis obtained through EUS-guided aspiration aids characterization. Elevated carcinoembryonic antigen (CEA) above 192 ng/mL strongly suggests mucinous neoplasm (MCN or IPMN). Low amylase suggests a non-communicating cyst (MCN rather than IPMN). Cytology may demonstrate mucin or dysplastic cells.

Solid pseudopapillary neoplasms occur predominantly in young women and demonstrate low malignant potential. Surgical resection is curative in most cases.

<image>Panel A: Pancreatic cystic lesion classification showing pseudocyst, serous cystadenoma (microcystic with central scar), mucinous cystic neoplasm (women, body/tail, ovarian stroma), IPMN, and solid pseudopapillary neoplasm with representative imaging. Panel B: IPMN subtypes showing main duct (dilated MPD greater than 5 mm, 40-70% malignancy risk), branch duct (lower 15-25% risk), and mixed type with management implications. Panel C: Branch duct IPMN management algorithm with high-risk stigmata requiring surgery, worrisome features prompting EUS, and surveillance for unconcerning features. Panel D: Cyst fluid analysis interpretation with CEA (greater than 192 suggesting mucinous), amylase (high suggesting duct communication), and cytology findings.</image>

Pancreatic Cancer

Pancreatic ductal adenocarcinoma represents one of the most lethal malignancies, ranking as the fourth leading cause of cancer death with overall five-year survival of only ten to twelve percent. This poor prognosis reflects late presentation, aggressive biology, and limited treatment efficacy.

Epidemiologically, ductal adenocarcinoma accounts for approximately ninety percent of pancreatic malignancies. The incidence increases with age, with most cases diagnosed after age sixty. Tumor location favors the head (seventy percent), followed by the body (twenty percent) and tail (ten percent). Head lesions present earlier due to biliary obstruction, while body and tail lesions grow silently until quite advanced.

Risk factors span genetic and environmental domains. Cigarette smoking doubles pancreatic cancer risk and represents the most important modifiable factor. Chronic pancreatitis, regardless of etiology, increases long-term risk. Family history, particularly with two or more first-degree relatives affected, substantially elevates risk. Hereditary syndromes conferring increased risk include BRCA1 and BRCA2 mutations (also associated with breast and ovarian cancer), Lynch syndrome, familial atypical multiple mole melanoma (FAMMM) syndrome, and Peutz-Jeghers syndrome. Obesity and type 2 diabetes are associated with increased risk. Notably, new-onset diabetes in an adult, particularly when unexplained by weight gain or other factors, may herald occult pancreatic cancer and should prompt evaluation.

Clinical presentation varies by tumor location. Pancreatic head lesions classically present with painless jaundice as the growing tumor obstructs the intrapancreatic common bile duct. Weight loss is nearly universal and often substantial. Pain, when present, indicates locally advanced disease with neural involvement, manifesting as epigastric or back pain. New-onset diabetes develops in twenty-five to thirty percent of patients. Courvoisier's sign describes a palpable, non-tender gallbladder in a jaundiced patient, suggesting malignant biliary obstruction (the chronically diseased gallbladder in cholelithiasis does not distend). Trousseau's sign refers to migratory superficial thrombophlebitis, reflecting the hypercoagulable state associated with pancreatic cancer.

Diagnosis and staging employ multimodal imaging. CT with pancreas protocol (arterial and portal venous phases with thin cuts through the pancreas) serves as the primary study for diagnosis, assessment of vascular involvement, and staging. MRI with MRCP provides alternative evaluation and superior biliary imaging. Endoscopic ultrasound enables tissue acquisition through fine needle aspiration when histologic diagnosis is required. CA 19-9 is the primary serum marker; while not useful for screening or definitive diagnosis, elevated levels carry prognostic significance and can be followed for treatment response. PET scanning has a limited role but may identify occult metastases in selected cases.

Staging categorizes patients by resectability. Resectable tumors have no arterial involvement and limited or no venous involvement. Borderline resectable tumors have arterial abutment or venous involvement amenable to reconstruction. Locally advanced tumors have arterial encasement or unreconstructible venous involvement without distant metastases. Metastatic disease includes liver, peritoneal, or distant nodal involvement.

Treatment follows staging. Resectable disease undergoes surgical resection: pancreaticoduodenectomy (Whipple procedure) for head lesions or distal pancreatectomy with splenectomy for body and tail lesions. Adjuvant chemotherapy with modified FOLFIRINOX or gemcitabine-based regimens improves survival. Neoadjuvant therapy is increasingly used for borderline resectable disease and even some resectable cases to improve resection margins and treat micrometastatic disease. Locally advanced disease receives chemotherapy with or without radiation. Metastatic disease is treated with palliative systemic therapy (FOLFIRINOX or gemcitabine-nab-paclitaxel in patients with good performance status). Palliative care addresses symptom burden: biliary stenting relieves jaundice and pruritus, celiac plexus neurolysis treats refractory pain, and nutritional support with PERT addresses exocrine insufficiency.

<image>Panel A: Epidemiology showing ductal adenocarcinoma (90%), location distribution (head 70%, body 20%, tail 10%), and 10-12% five-year survival, with risk factors including smoking, chronic pancreatitis, family history, and hereditary syndromes. Panel B: Clinical presentation with painless jaundice from head lesions, weight loss, pain indicating neural invasion, new-onset diabetes, Courvoisier sign, and Trousseau sign. Panel C: Diagnostic approach with CT pancreas protocol, EUS with FNA, and CA 19-9 utility and limitations. Panel D: Staging and treatment algorithm from resectable (Whipple or distal pancreatectomy with adjuvant chemotherapy) through borderline resectable (neoadjuvant therapy), locally advanced, and metastatic disease with palliative management.</image>

Pancreatic Neuroendocrine Tumors

Pancreatic neuroendocrine tumors arise from the islet cells and demonstrate markedly different biology from ductal adenocarcinoma. While potentially malignant, many PNETs grow slowly, and even patients with metastatic disease may survive for years with appropriate management.

PNETs are classified as functional (forty to fifty percent) or non-functional (fifty to sixty percent) based on whether they produce hormones causing clinical syndromes. Non-functional tumors, despite not causing hormonal symptoms, may produce chromogranin A and other markers; they typically present with mass effect, including abdominal pain, jaundice, or incidental detection on imaging.

Among functional tumors, insulinomas are the most common, producing excess insulin and causing hypoglycemia. The classic presentation involves Whipple's triad: symptoms consistent with hypoglycemia, documented low blood glucose during symptoms, and resolution with glucose administration. Diagnosis requires demonstrating inappropriately elevated insulin and C-peptide during hypoglycemia. Most insulinomas are benign and solitary.

Gastrinomas secrete gastrin, producing Zollinger-Ellison syndrome characterized by severe peptic ulcer disease (often multiple or atypical location ulcers), gastroesophageal reflux, and secretory diarrhea from acid hypersecretion. The majority occur in the "gastrinoma triangle" bounded by the junction of the cystic and common bile ducts, the junction of the second and third portions of the duodenum, and the junction of the neck and body of the pancreas. A significant proportion are malignant.

Glucagonomas produce the 4D syndrome: Diabetes, Deep vein thrombosis, Depression, and the characteristic Dermatitis known as necrolytic migratory erythema. VIPomas secrete vasoactive intestinal peptide, causing WDHA syndrome (Watery Diarrhea, Hypokalemia, Achlorhydria). Somatostatinomas are rare and cause diabetes, steatorrhea, and cholelithiasis.

MEN1 syndrome (multiple endocrine neoplasia type 1) associates with pancreatic neuroendocrine tumors alongside pituitary adenomas and parathyroid hyperplasia. PNETs in MEN1 are often multiple and may be gastrinomas or non-functional tumors. Patients with known MEN1 require regular pancreatic imaging surveillance.

Diagnosis employs imaging and biochemical testing. CT or MRI identifies and stages tumors. Specific hormone levels confirm functional tumor type. Chromogranin A serves as a general PNET marker. Gallium-68 DOTATATE PET imaging, which binds somatostatin receptors expressed by most well-differentiated PNETs, provides highly sensitive localization and staging. Endoscopic ultrasound helps localize small tumors, particularly insulinomas.

Treatment depends on grade, stage, and functional status. Surgical resection offers potential cure for localized disease. For advanced or unresectable disease, somatostatin analogs (octreotide, lanreotide) control hormonal symptoms and may exert anti-tumor effects. mTOR inhibitors (everolimus) and tyrosine kinase inhibitors (sunitinib) provide additional systemic options. Peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE delivers targeted radiation to somatostatin receptor-expressing tumors and has demonstrated significant efficacy in metastatic disease.

<image>Panel A: PNET classification showing functional (40-50%) versus non-functional (50-60%) tumors with functional types listed (insulinoma, gastrinoma, glucagonoma, VIPoma, somatostatinoma). Panel B: Functional tumor syndromes including insulinoma (Whipple's triad), gastrinoma (Zollinger-Ellison syndrome with gastrinoma triangle), glucagonoma (4D syndrome), VIPoma (WDHA syndrome), and somatostatinoma. Panel C: MEN1 association with pituitary-parathyroid-pancreas diagram and surveillance recommendations alongside diagnostic imaging (CT/MRI, Ga-68 DOTATATE PET, EUS). Panel D: Treatment algorithm from surgery for localized disease to somatostatin analogs, systemic therapy (everolimus, sunitinib), and Lu-177 DOTATATE PRRT for advanced disease.</image>

Summary

Acute pancreatitis results most commonly from gallstones (forty percent) and alcohol (thirty percent), diagnosed when two of three criteria are met: characteristic pain, lipase greater than three times normal, and imaging findings. Management centers on aggressive fluid resuscitation with lactated Ringer's, early enteral nutrition, and avoidance of prophylactic antibiotics in sterile necrosis.

Complications evolve over time: acute peripancreatic fluid collections and acute necrotic collections occur within four weeks, maturing to pseudocysts (fluid only) or walled-off necrosis (containing debris) after four weeks. Infected necrosis is managed with a step-up approach from antibiotics through drainage to surgical debridement.

Chronic pancreatitis causes irreversible damage with calcifications, ductal abnormalities, and eventual exocrine (steatorrhea when greater than ninety percent function lost, managed with PERT) and endocrine (brittle diabetes) insufficiency. Alcohol accounts for seventy percent of cases.

Autoimmune pancreatitis includes Type 1 (IgG4-related, older males, extrapancreatic involvement) and Type 2 (pancreas-specific, IBD association). Both respond dramatically to corticosteroids.

Pancreatic cystic lesions require risk stratification. Main duct IPMNs carry high malignancy risk and require resection. Branch duct IPMNs are managed based on worrisome features and high-risk stigmata.

Pancreatic ductal adenocarcinoma carries poor prognosis (ten to twelve percent five-year survival). Head lesions present with painless jaundice. Treatment is surgical resection when feasible, with adjuvant chemotherapy, and neoadjuvant therapy increasingly used for borderline resectable disease.

Pancreatic neuroendocrine tumors may be functional (insulinoma, gastrinoma, glucagonoma, VIPoma) or non-functional. Treatment includes surgery for localized disease and somatostatin analogs, targeted therapies, or PRRT for advanced disease.

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown